Physician profile
James Hall
NPI 1538142179
$3,935.94
in general payments reported to CMS, 2019-2025
12 companies · $222 in 2025
The $222 reported for 2025 was less than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $611 · 2020: $514 · 2021: $788 · 2022: $1,274 · 2023: $344 · 2024: $183 · 2025: $222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $749.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $749.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| US Retina LLC | $2,121.33 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $663.56 | 2019-2025 | Eylea, Eylea Hd |
| Genentech USA, INC. | $334.94 | 2019-2025 | Vabysmo |
| Novartis Pharmaceuticals Corporation | $165.34 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $140.47 | 2022-2025 | Xipere, Visudyne |
| Alimera Sciences, INC. | $127.62 | 2019-2024 | Iluvien, Yutiq |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $94.35 | 2019-2021 | |
| Apellis Pharmaceuticals, INC. | $81.70 | 2023-2024 | Syfovre |
| Abbvie INC. | $69.89 | 2024-2025 | |
| Astellas Pharma US INC | $60.23 | 2025 | Izervay |
| Allergan, INC. | $58.73 | 2019 | |
| Sun Pharmaceutical Industries INC. | $17.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$78,085.07 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.